{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:34:08Z","timestamp":1788950048077,"version":"build-2803163510"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11934-025-01264-6","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T04:11:39Z","timestamp":1744258299000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Management of Patients with Muscle-Invasive Bladder Cancer Achieving A Clinical Complete Response after Neoadjuvant Therapy: Evidence and Consideration for Active Surveillance"],"prefix":"10.1007","volume":"26","author":[{"given":"Benjamin I.","family":"Joffe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Christin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mentine","family":"Le Coz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinath-Reddi","family":"Pingle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander Z.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karie D.","family":"Runcie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark N.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guarionex Joel","family":"DeCastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"McKiernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Lenis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"1264_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, et al. Cancer statistics, 2025. CA: Cancer J Clin. 2025;75:1\u201345.","journal-title":"CA: Cancer J Clin"},{"key":"1264_CR2","first-page":"1980","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis AT, Lec PM, Chamie K. Bladder Cancer JAMA. 2020;324:1980\u201391.","journal-title":"Bladder Cancer JAMA"},{"key":"1264_CR3","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/bju.12601","volume":"114","author":"AB Smith","year":"2014","unstructured":"Smith AB, Deal AM, Woods ME, Wallen EM, Pruthi RS, Chen RC, et al. Bladder cancer treatment and survival: evaluating treatment and survival in the National cancer data base. BJU Int. 2014;114:719\u201326.","journal-title":"BJU Int"},{"key":"1264_CR4","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1200\/JCO.22.02762","volume":"41","author":"JP Stein","year":"2001","unstructured":"Stein JP, Lieskovsky G, Cote R, Groshen S, Feng A-C, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-Term results in 1,054 patients. J Clin Oncol. 2001;41:3772\u201381.","journal-title":"J Clin Oncol"},{"key":"1264_CR5","doi-asserted-by":"crossref","unstructured":"Holzbeierlein J, Bixler BR, Buckley DI, Chang SS, Holmes RS, James AC et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA\/ASCO\/SUO GUIDELINE (2017; Amended 2020, 2024). J Urol. 2024;101097JU0000000000003981.","DOI":"10.1097\/JU.0000000000003981"},{"key":"1264_CR6","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.eururo.2014.05.031","volume":"66","author":"HM Bruins","year":"2014","unstructured":"Bruins HM, Veskimae E, Hernandez V, Imamura M, Neuberger MM, Dahm P, et al. The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: A systematic review. Eur Urol. 2014;66:1065\u201377.","journal-title":"Eur Urol"},{"key":"1264_CR7","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859\u201366.","journal-title":"N Engl J Med"},{"key":"1264_CR8","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","volume":"21","author":"M Yin","year":"2016","unstructured":"Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA, et al. Neoadjuvant chemotherapy for Muscle-Invasive bladder cancer: A systematic review and Two\u2010Step Meta\u2010Analysis. Oncol. 2016;21:708\u201315.","journal-title":"Oncol"},{"key":"1264_CR9","doi-asserted-by":"crossref","unstructured":"Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Lucian\u00f2 R et al. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. J Clin Oncol. 2018;36:JCO.18.01148.","DOI":"10.1200\/JCO.18.01148"},{"key":"1264_CR10","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2008.07.031","volume":"55","author":"A Shabsigh","year":"2009","unstructured":"Shabsigh A, Korets R, Vora KC, Brooks CM, Cronin AM, Savage C, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol. 2009;55:164\u201376.","journal-title":"Eur Urol"},{"key":"1264_CR11","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/S0022-5347(05)00421-0","volume":"175","author":"ML Quek","year":"2006","unstructured":"Quek ML, Stein JP, Daneshmand S, Miranda G, Thangathurai D, Roffey P, et al. A critical analysis of perioperative mortality from radical cystectomy. J Urol. 2006;175:886\u201390.","journal-title":"J Urol"},{"key":"1264_CR12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.euo.2023.02.008","volume":"6","author":"E Grobet-Jeandin","year":"2023","unstructured":"Grobet-Jeandin E, Lenfant L, Mir C, Giannarini G, Alcaraz A, Albersen M, et al. A systematic review of oncological outcomes associated with bladder-sparing strategies in patients achieving complete clinical response to initial systemic treatment for localized Muscle-invasive bladder cancer. Eur Urol Oncol. 2023;6:251\u201362.","journal-title":"Eur Urol Oncol"},{"key":"1264_CR13","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.euf.2019.08.009","volume":"6","author":"JS Winoker","year":"2020","unstructured":"Winoker JS, Liaw CW, Galsky MD, Wiklund P, Mehrazin R. Clinical complete response after neoadjuvant chemotherapy for Muscle-invasive bladder cancer: A call for standardized assessments and definitions. Eur Urol Focus. 2020;6:627\u20139.","journal-title":"Eur Urol Focus"},{"key":"1264_CR14","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.euf.2016.12.005","volume":"4","author":"JB Kukreja","year":"2018","unstructured":"Kukreja JB, Porten S, Golla V, Ho PL, Noguera-Gonzalez G, Navai N, et al. Absence of tumor on repeat transurethral resection of bladder tumor does not predict final pathologic T0 stage in bladder cancer treated with radical cystectomy. Eur Urol Focus. 2018;4:720\u20134.","journal-title":"Eur Urol Focus"},{"key":"1264_CR15","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.eururo.2020.07.016","volume":"79","author":"REN Becker","year":"2021","unstructured":"Becker REN, Meyer AR, Brant A, Reese AC, Biles MJ, Harris KT, et al. Clinical restaging and tumor sequencing are inaccurate indicators of response to neoadjuvant chemotherapy for Muscle-invasive bladder cancer. Eur Urol. 2021;79:364\u201371.","journal-title":"Eur Urol"},{"key":"1264_CR16","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1097\/JU.0000000000001602","volume":"205","author":"M Zibelman","year":"2021","unstructured":"Zibelman M, Asghar AM, Parker DC, O\u2019Neill J, Wei S, Greenberg RE, et al. Cystoscopy and systematic bladder tissue sampling in predicting pT0 bladder cancer: A prospective trial. J Urol. 2021;205:1605\u201311.","journal-title":"J Urol"},{"key":"1264_CR17","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.1007\/s00330-020-06802-z","volume":"30","author":"C Luo","year":"2020","unstructured":"Luo C, Huang B, Wu Y, Chen J, Chen L. Use of vesical Imaging-Reporting and data system (VI-RADS) for detecting the muscle invasion of bladder cancer: a diagnostic meta-analysis. Eur Radiol. 2020;30:4606\u201314.","journal-title":"Eur Radiol"},{"key":"1264_CR18","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00261-021-03365-5","volume":"47","author":"M Pecoraro","year":"2022","unstructured":"Pecoraro M, Giudice FD, Magliocca F, Simone G, Flammia S, Leonardo C, et al. Vesical Imaging-Reporting and data system (VI-RADS) for assessment of response to systemic therapy for bladder cancer: preliminary report. Abdom Radiol. 2022;47:763\u201370.","journal-title":"Abdom Radiol"},{"key":"1264_CR19","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/bju.16191","volume":"133","author":"A Necchi","year":"2024","unstructured":"Necchi A, Basile G, Gibb EA, Raggi D, Calareso G, de Padua TC, et al. Vesical Imaging-Reporting and data system use predicting the outcome of neoadjuvant pembrolizumab in muscle\u2010invasive bladder cancer. BJU Int. 2024;133:214\u201322.","journal-title":"BJU Int"},{"key":"1264_CR20","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/s41585-023-00830-2","volume":"21","author":"V Panebianco","year":"2024","unstructured":"Panebianco V, Briganti A, Boellaard TN, Catto J, Comperat E, Efstathiou J, et al. Clinical application of bladder MRI and the vesical Imaging-Reporting and data system. Nat Rev Urol. 2024;21:243\u201351.","journal-title":"Nat Rev Urol"},{"key":"1264_CR21","doi-asserted-by":"publisher","first-page":"e62713","DOI":"10.1016\/j.crad.2021.03.001","volume":"76","author":"SJ Choi","year":"2021","unstructured":"Choi SJ, Park KJ, Heo C, Park BW, Kim M, Kim JK. Radiomics-based model for predicting pathological complete response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. Clin Radiol. 2021;76:e62713\u201321.","journal-title":"Clin Radiol"},{"key":"1264_CR22","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.clgc.2018.05.008","volume":"16","author":"A Soubra","year":"2018","unstructured":"Soubra A, Gencturk M, Froelich J, Balaji P, Gupta S, Jha G, et al. FDG-PET\/CT for assessing the response to neoadjuvant chemotherapy in bladder cancer patients. Clin Genitourin Cancer. 2018;16:360\u20134.","journal-title":"Clin Genitourin Cancer"},{"key":"1264_CR23","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1007\/s00259-022-05761-5","volume":"49","author":"LM Unterrainer","year":"2022","unstructured":"Unterrainer LM, Lindner S, Eismann L, Casuscelli J, Gildehaus F-J, Bui VN, et al. Feasibility of [68Ga]Ga-FAPI-46 PET\/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma. Eur J Nucl Med Mol Imaging. 2022;49:3571\u201380.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1264_CR24","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s11307-022-01715-3","volume":"24","author":"E Novruzov","year":"2022","unstructured":"Novruzov E, Dendl K, Ndlovu H, Choyke PL, Dabir M, Beu M, et al. Head-to-head Intra-individual comparison of [68Ga]-FAPI and [18F]-FDG PET\/CT in patients with bladder cancer. Mol Imaging Biol. 2022;24:651\u20138.","journal-title":"Mol Imaging Biol"},{"key":"1264_CR25","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1158\/1078-0432.CCR-23-0609","volume":"29","author":"X Duan","year":"2023","unstructured":"Duan X, Xia L, Zhang Z, Ren Y, Pomper MG, Rowe SP, et al. First-in-Human study of the radioligand 68Ga-N188 targeting Nectin-4 for PET\/CT imaging of advanced urothelial carcinoma. Clin Cancer Res. 2023;29:3395\u2013407.","journal-title":"Clin Cancer Res"},{"key":"1264_CR26","unstructured":"ClinicalTrials.gov [Internet]. Available from: https:\/\/clinicaltrials.gov\/."},{"key":"1264_CR27","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S0302-2838(02)00006-4","volume":"41","author":"M-P Raitanen","year":"2002","unstructured":"Raitanen M-P, Aine R, Rintala E, Kallio J, Rajala P, Juusela H, et al. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol. 2002;41:284\u20139.","journal-title":"Eur Urol"},{"key":"1264_CR28","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.euo.2019.06.017","volume":"3","author":"J Palou","year":"2020","unstructured":"Palou J, Brausi M, Catto JWF. Management of patients with normal cystoscopy but positive cytology or urine markers. Eur Urol Oncol. 2020;3:548\u201354.","journal-title":"Eur Urol Oncol"},{"key":"1264_CR29","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1245\/s10434-016-5763-5","volume":"24","author":"A Gopalakrishna","year":"2017","unstructured":"Gopalakrishna A, Fantony JJ, Longo TA, Owusu R, Foo W-C, Dash R, et al. Anticipatory positive urine tests for bladder cancer. Ann Surg Oncol. 2017;24:1747\u201353.","journal-title":"Ann Surg Oncol"},{"key":"1264_CR30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2016.01.007","volume":"70","author":"K Birkenkamp-Demtr\u00f6der","year":"2016","unstructured":"Birkenkamp-Demtr\u00f6der K, Nordentoft I, Christensen E, H\u00f8yer S, Reinert T, Vang S, et al. Genomic alterations in liquid biopsies from patients with bladder cancer. Eur Urol. 2016;70:75\u201382.","journal-title":"Eur Urol"},{"key":"1264_CR31","doi-asserted-by":"publisher","first-page":"JCO1802052","DOI":"10.1200\/JCO.18.02052","volume":"37","author":"E Christensen","year":"2019","unstructured":"Christensen E, Birkenkamp-Demtr\u00f6der K, Sethi H, Shchegrova S, Salari R, Nordentoft I, et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by Ultra-Deep sequencing of plasma Cell-Free DNA in patients with urothelial bladder carcinoma. J Clin Oncol. 2019;37:JCO1802052.","journal-title":"J Clin Oncol"},{"key":"1264_CR32","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.eururo.2017.09.011","volume":"73","author":"K Birkenkamp-Demtr\u00f6der","year":"2018","unstructured":"Birkenkamp-Demtr\u00f6der K, Christensen E, Nordentoft I, Knudsen M, Taber A, H\u00f8yer S, et al. Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis. Eur Urol. 2018;73:535\u201340.","journal-title":"Eur Urol"},{"key":"1264_CR33","first-page":"CD","volume":"9","author":"JC Dudley","year":"2018","unstructured":"Dudley JC, Schroers-Martin J, Lazzareschi DV, Shi WY, Chen SB, Esfahani MS, et al. Detection and surveillance of bladder cancer using urine tumor DNA. Cancer Discov. 2018;9:CD\u201318.","journal-title":"Cancer Discov"},{"key":"1264_CR34","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1158\/1078-0432.CCR-22-3250","volume":"29","author":"E Christensen","year":"2023","unstructured":"Christensen E, Nordentoft I, Birkenkamp-Demtroder K, Elb\u00e6k SK, Lindskrog SV, Taber A, et al. Cell-free urine and plasma DNA mutational analysis predicts neoadjuvant chemotherapy response and outcome in patients with muscle invasive bladder cancer. Clin Cancer Res. 2023;29:1582\u201391.","journal-title":"Clin Cancer Res"},{"key":"1264_CR35","doi-asserted-by":"publisher","first-page":"e2300362","DOI":"10.1200\/PO.23.00362","volume":"8","author":"U Satyal","year":"2024","unstructured":"Satyal U, Valentine H, Liu D, Slifker M, Lallas CD, Trabulsi EJ, et al. Urine biopsy as dynamic biomarker to enhance clinical staging of bladder cancer in radical cystectomy candidates. JCO Precis Oncol. 2024;8:e2300362.","journal-title":"JCO Precis Oncol"},{"key":"1264_CR36","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","volume":"85","author":"T Powles","year":"2024","unstructured":"Powles T, Assaf ZJ, Degaonkar V, Grivas P, Hussain M, Oudard S, et al. Updated overall survival by Circulating tumor DNA status from the phase 3 IMvigor010 trial: adjuvant Atezolizumab versus observation in Muscle-invasive urothelial carcinoma. Eur Urol. 2024;85:114\u201322.","journal-title":"Eur Urol"},{"key":"1264_CR37","doi-asserted-by":"crossref","unstructured":"Elshabrawy A, Wang H, Satsangi A, Wheeler K, Ramamurthy C, Pruthi D et al. Correlates of refusal of radical cystectomy in patients with muscle-invasive bladder cancer. Urol Oncol: Semin Orig Investig. 2021;39:236.e9-236.e20.","DOI":"10.1016\/j.urolonc.2020.11.023"},{"key":"1264_CR38","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.juro.2018.05.078","volume":"200","author":"P Mazza","year":"2018","unstructured":"Mazza P, Moran GW, Li G, Robins DJ, Matulay JT, Herr HW, et al. Conservative management following complete clinical response to neoadjuvant chemotherapy of muscle invasive bladder cancer: contemporary outcomes of a Multi-Institutional cohort study. J Urol. 2018;200:1005\u201313.","journal-title":"J Urol"},{"key":"1264_CR39","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.eururo.2008.08.027","volume":"55","author":"E Solsona","year":"2009","unstructured":"Solsona E, Climent MA, Iborra I, Collado A, Rubio J, Ric\u00f3s JV, et al. Bladder preservation in selected patients with Muscle-Invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: Long-Term Follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy. Eur Urol. 2009;55:911\u201321.","journal-title":"Eur Urol"},{"key":"1264_CR40","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.eururo.2007.12.031","volume":"54","author":"HW Herr","year":"2008","unstructured":"Herr HW. Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for Muscle-Invasive bladder cancer. Eur Urol. 2008;54:126\u201332.","journal-title":"Eur Urol"},{"key":"1264_CR41","doi-asserted-by":"crossref","unstructured":"Joffe BI, Laplaca C, Chung R, Ingram J, Kurtzman JT, DeCastro GJ, NON-MUSCLE INVASIVE RECURRENCE AND MANAGEMENT DURING SURVEILLANCE IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ACHIEVE CLINICAL COMPLETE RESPONSE TO NEOADJUVANT CHEMOTHERAPY. Urol Oncol: Semin Orig Investig. 2024;42:S33.","DOI":"10.1016\/j.urolonc.2024.01.115"},{"key":"1264_CR42","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.suronc.2016.05.027","volume":"25","author":"LS Yang","year":"2016","unstructured":"Yang LS, Shan BL, Shan LL, Chin P, Murray S, Ahmadi N, et al. A systematic review and meta-analysis of quality of life outcomes after radical cystectomy for bladder cancer. Surg Oncol. 2016;25:281\u201397.","journal-title":"Surg Oncol"},{"key":"1264_CR43","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.eururo.2021.09.018","volume":"81","author":"MB Clements","year":"2022","unstructured":"Clements MB, Atkinson TM, Dalbagni GM, Li Y, Vickers AJ, Herr HW, et al. Health-related quality of life for patients undergoing radical cystectomy: results of a large prospective cohort. Eur Urol. 2022;81:294\u2013304.","journal-title":"Eur Urol"},{"key":"1264_CR44","doi-asserted-by":"crossref","unstructured":"Lynch NB, Neckonoff E, Bai K, Laplaca C, Pingle S-R, Joffe BI, DECISIONAL REGRET, AND FEAR OF RECURRENCE IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER MANAGED WITH SURVEILLANCE AFTER CLINICAL COMPLETE RESPONSE TO NEOADJUVANT CHEMOTHERAPY. QUALITY OF LIFE,. Urol Oncol: Semin Orig Investig. 2025;43:16.","DOI":"10.1016\/j.urolonc.2024.12.041"},{"key":"1264_CR45","doi-asserted-by":"crossref","unstructured":"Chung R, Kurtzman JT, Joffe BI, Vila-Reyes H, Miles CH, DeCastro GJ et al. Long-Term oncologic outcomes in patients with muscle invasive bladder cancer misclassified as achieving a complete clinical response to neoadjuvant chemotherapy. JU Open Plus. 2024;2.","DOI":"10.1097\/JU9.0000000000000180"},{"key":"1264_CR46","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"JA Witjes","year":"2024","unstructured":"Witjes JA, Bruins HM, Carri\u00f3n A, Cathomas R, Comp\u00e9rat E, Efstathiou JA, et al. European association of urology guidelines on Muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur Urol. 2024;85:17\u201331.","journal-title":"Eur Urol"},{"key":"1264_CR47","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.eururo.2014.02.038","volume":"66","author":"G Ploussard","year":"2014","unstructured":"Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, R\u00f6del CM, et al. Critical analysis of bladder sparing with trimodal therapy in Muscle-invasive bladder cancer: A systematic review. Eur Urol. 2014;66:120\u201337.","journal-title":"Eur Urol"},{"key":"1264_CR48","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1158\/1078-0432.CCR-22-2158","volume":"28","author":"G Basile","year":"2022","unstructured":"Basile G, Bandini M, Gibb EA, Ross JS, Raggi D, Marandino L, et al. Neoadjuvant pembrolizumab and radical cystectomy in patients with Muscle-Invasive urothelial bladder cancer: 3-Year median Follow-Up update of PURE-01 trial. Clin Cancer Res. 2022;28:5107\u201314.","journal-title":"Clin Cancer Res"},{"key":"1264_CR49","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","volume":"82","author":"B Szabados","year":"2022","unstructured":"Szabados B, Kockx M, Assaf ZJ, Dam P-J, van, Rodriguez-Vida A, Duran I, et al. Final results of neoadjuvant Atezolizumab in Cisplatin-ineligible patients with Muscle-invasive urothelial cancer of the bladder. Eur Urol. 2022;82:212\u201322.","journal-title":"Eur Urol"},{"key":"1264_CR50","doi-asserted-by":"publisher","first-page":"5384","DOI":"10.1158\/1078-0432.CCR-14-1298","volume":"20","author":"AR de Biasi","year":"2014","unstructured":"de Biasi AR, Villena-Vargas J, Adusumilli PS. Cisplatin-Induced antitumor Immunomodulation: A review of preclinical and clinical evidence. Clin Cancer Res. 2014;20:5384\u201391.","journal-title":"Clin Cancer Res"},{"key":"1264_CR51","unstructured":"Galsky MD, Daneshmand S, Izadmehr S, Gonzalez-Kozlova E, Chan KG, Lewis S et al. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial. Nat Med. 2023;1\u201310."},{"key":"1264_CR52","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/JCO.22.01792","volume":"41","author":"T Powles","year":"2023","unstructured":"Powles T, Park SH, Caserta C, Valderrama BP, Gurney H, Ull\u00e9n A, et al. Avelumab First-Line maintenance for advanced urothelial carcinoma: results from the JAVELIN bladder 100 trial after \u2265 2 years of Follow-Up. J Clin Oncol. 2023;41:3486\u201392.","journal-title":"J Clin Oncol"},{"key":"1264_CR53","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. Enfortumab Vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390:875\u201388.","journal-title":"N Engl J Med"},{"key":"1264_CR54","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.1200\/JCO.2023.41.16_suppl.4595","volume":"41","author":"TW Flaig","year":"2023","unstructured":"Flaig TW, Rosenberg JE, Hoimes CJ, O\u2019Donnell PH, Mar N, Gourdin TS, et al. Study EV-103: neoadjuvant treatment with enfortumab Vedotin monotherapy in cisplatin-ineligible patients (pts) with muscle invasive bladder cancer (MIBC): updated results for cohort H. J Clin Oncol. 2023;41:4595\u20134595.","journal-title":"J Clin Oncol"},{"key":"1264_CR55","doi-asserted-by":"publisher","first-page":"TPS587","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS587","volume":"40","author":"CJ Hoimes","year":"2022","unstructured":"Hoimes CJ, Flaig TW, Srinivas S, Mar N, Petrylak DP, O\u2019Donnell PH, et al. Study EV-103 cohort L: evaluating perioperative enfortumab Vedotin monotherapy in cis-ineligible muscle invasive bladder cancer (MIBC) (trial in progress). J Clin Oncol. 2022;40:TPS587\u2013587.","journal-title":"J Clin Oncol"},{"key":"1264_CR56","doi-asserted-by":"publisher","first-page":"TPS588","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS588","volume":"41","author":"CJ Hoimes","year":"2023","unstructured":"Hoimes CJ, Loriot Y, Bedke J, Nishiyama H, Kataria RS, Moreno BH, et al. Perioperative enfortumab Vedotin (EV) plus pembrolizumab (pembro) versus chemotherapy in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): phase 3 KEYNOTE-B15\/EV-304. J Clin Oncol. 2023;41:TPS588\u2013588.","journal-title":"J Clin Oncol"},{"key":"1264_CR57","doi-asserted-by":"crossref","unstructured":"Cigliola A, Moschini M, Tateo V, Mercinelli C, Patan\u00e8 D, Crupi E et al. Perioperative sacituzumab Govitecan (SG) alone or in combination with pem-brolizumab (Pembro) for patients with muscle-invasive urothelial bladder cancer(MIBC): SURE-01\/02 interim results. J Clin Oncol. 2024.","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4517"},{"key":"1264_CR58","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","volume":"68","author":"ER Plimack","year":"2015","unstructured":"Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, et al. Defects in DNA repair genes predict response to neoadjuvant Cisplatin-based chemotherapy in Muscle-invasive bladder cancer. Eur Urol. 2015;68:959\u201367.","journal-title":"Eur Urol"},{"key":"1264_CR59","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.1200\/JCO.2022.40.16_suppl.4581","volume":"40","author":"ER Plimack","year":"2022","unstructured":"Plimack ER, Tangen C, Plets M, Kokate R, Xiu J, Nabhan C, et al. S1314 correlative analysis of ATM, RB1, ERCC2, and FANCC mutations and pathologic complete response (pT0) at cystectomy after neoadjuvant chemotherapy (NAC) in patients with muscle invasive bladder cancer (MIBC): implications for bladder preservation. J Clin Oncol. 2022;40:4581\u20134581.","journal-title":"J Clin Oncol"},{"key":"1264_CR60","doi-asserted-by":"publisher","first-page":"4522","DOI":"10.1200\/JCO.2022.40.16_suppl.4522","volume":"40","author":"G Iyer","year":"2022","unstructured":"Iyer G, Tangen C, Sarfaty M, Regazzi AM, Lee I-LC, Choi W, et al. Association of DNA damage response (DDR) gene mutations (mts) and response to neoadjuvant cisplatin-based chemotherapy (chemo) in muscle-invasive bladder cancer (MIBC) patients (pts) enrolled onto SWOG S1314. J Clin Oncol. 2022;40:4522\u20134522.","journal-title":"J Clin Oncol"},{"key":"1264_CR61","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1200\/JCO.2017.75.0158","volume":"36","author":"G Iyer","year":"2018","unstructured":"Iyer G, Balar AV, Milowsky MI, Bochner BH, Dalbagni G, Donat SM, et al. Multicenter prospective phase II trial of neoadjuvant Dose-Dense gemcitabine plus cisplatin in patients with Muscle-Invasive bladder cancer. J Clin Oncol. 2018;36:1949\u201356.","journal-title":"J Clin Oncol"},{"key":"1264_CR62","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/jamaoncol.2016.1056","volume":"2","author":"D Liu","year":"2016","unstructured":"Liu D, Plimack ER, Hoffman-Censits J, Garraway LA, Bellmunt J, Allen EV, et al. Clinical validation of chemotherapy response biomarker ERCC2 in Muscle-Invasive urothelial bladder carcinoma. JAMA Oncol. 2016;2:1094.","journal-title":"JAMA Oncol"},{"key":"1264_CR63","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","volume":"4","author":"EMV Allen","year":"2014","unstructured":"Allen EMV, Mouw KW, Kim P, Iyer G, Wagle N, Al-Ahmadie H, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in Muscle-Invasive urothelial carcinoma. Cancer Discov. 2014;4:1140\u201353.","journal-title":"Cancer Discov"},{"key":"1264_CR64","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1200\/JCO.2023.41.6_suppl.438","volume":"41","author":"DM Geynisman","year":"2023","unstructured":"Geynisman DM, Abbosh P, Ross EA, Zibelman MR, Ghatalia P, Anari F, et al. A phase II trial of risk-enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN). J Clin Oncol. 2023;41:438\u2013438.","journal-title":"J Clin Oncol"},{"key":"1264_CR65","doi-asserted-by":"crossref","unstructured":"Plimack ER, Tangen C, Plets M, Kokate R, Xiu J, Nabhan C et al. Correlative analysis of ATM, RB1, ERCC2, and FANCC mutations and pathologic complete response after neoadjuvant chemotherapy in patients with Muscle-invasive bladder cancer: results from the SWOG S1314 trial. Eur Urol. 2024.","DOI":"10.1016\/j.eururo.2024.06.018"},{"key":"1264_CR66","doi-asserted-by":"publisher","first-page":"TPS4615","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4615","volume":"40","author":"G Iyer","year":"2022","unstructured":"Iyer G, Ballman KV, Atherton PJ, Murray K, Kwok Y, Steen PD, et al. A phase II study of gemcitabine plus cisplatin chemotherapy in patients with muscle-invasive bladder cancer with bladder preservation for those patients whose tumors harbor deleterious DNA damage response (DDR) gene alterations (Alliance A031701). J Clin Oncol. 2022;40:TPS4615\u20134615.","journal-title":"J Clin Oncol"},{"key":"1264_CR67","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/jnci\/djaa076","volume":"113","author":"M Bandini","year":"2020","unstructured":"Bandini M, Ross JS, Raggi D, Gallina A, Colecchia M, Lucian\u00f2 R, et al. Predicting the pathologic complete response after neoadjuvant pembrolizumab in Muscle-Invasive bladder cancer. JNCI: J Natl Cancer Inst. 2020;113:48\u201353.","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"1264_CR68","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1038\/s41467-024-48480-1","volume":"15","author":"W Beckabir","year":"2024","unstructured":"Beckabir W, Zhou M, Lee JS, Vensko SP, Woodcock MG, Wang H-H, et al. Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer. Nat Commun. 2024;15:4448.","journal-title":"Nat Commun"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-025-01264-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11934-025-01264-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-025-01264-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:02:54Z","timestamp":1767985374000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11934-025-01264-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1264"],"URL":"https:\/\/doi.org\/10.1007\/s11934-025-01264-6","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"27 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All reported studies\/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"AW is a consultant for Sanofi and Bicycle Therapeutics. Other authors have no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"36"}}